The Food and Drug Administration (FDA) approved Khapzory (levoleucovorin) injection, a folate analog for three indications.
The Food and Drug Administration (FDA) approved Khapzory (levoleucovorin) for injection for three indications.
The agent, which is a chemotherapy protective drug, is approved for the following:
“Khapzory is the first levoleucovorin product approved by the FDA that contains sodium in its formulation,” Joe Turgeon, president and chief executive officer of Spectrum Pharmaceuticals, the agent’s manufacturer, said in a statement. “This (new drug application) submission was part of the lifecycle management of our legacy product, Fusilev (levoleucovorin).”
For methotrexate toxicity, Khapzory is usually given every six hours for 10 doses. For colorectal cancer, the drug is usually given daily as a five-day treatment, repeated every four to five weeks.
Common side effects with Khapzory include nausea, vomiting, diarrhea or mouth sores.